David F. Kisor, Pharm.D., FCP

Dave Kisor, Professor of Pharmaceutical Sciences and Pharmacogenomics and Director of Pharmacogenomics at Manchester University, in Fort Wayne, IN. He is responsible for directing pharmacogenomics across programs in the College of Pharmacy, Natural and Health Sciences. Kisor led the development and implementation of the first dedicated Master of Science in Pharmacogenomics Program (MS in PGx) in the United States. He helped to expand delivery to an online format, as well as helping establishing the first dual degree (PharmD/PGx) program. He earned his Bachelor of Science degree in Pharmacy from The University of Toledo and his PharmD from The Ohio State University. He completed a postdoctoral fellowship in therapeutic drug monitoring and pharmacokinetics at Ohio State. He has integrated pharmacogenetics and pharmacogenomics with pharmacokinetic subject matter since 1998. Beyond the formal academic setting, he is very engaged in pharmacogenomics education, having been involved with the American Association of Colleges of Pharmacy Pharmacogenomics Special Interest Group (AACP PGx SIG) in defining/refining competency statements in genetics/genomics for pharmacists as well as leading the effort to provide the first certification program in PGx in the United States. Beyond AACP, Kisor is a member of the American Pharmacists Association (APhA), the American College of Clinical Pharmacology (ACCP), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and the Clinical Pharmacogenetics Implementation Consortium (CPIC). Kisor is a past chair of the AACP PGx SIG. He was named a fellow of ACCP in 2017.

Areas of interest/Recent projects

• Development of pharmacogenomics competencies of faculty
• Pharmacogenetics/Pharmacogenomics
• Pharmacogenetics
• Editor-in-Chief - Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process. Washington DC. American Pharmacists Association

Publications/Presentations/Posters

Book: (*Peer Reviewed):

• Kisor DF, Bright DR, Smith TR, Wiisanen K. Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process. Washington DC. American Pharmacists Association (©2020).*

• Kisor DF, Kane, MD, Talbot JT, Bright DR, Sprague JE. (2017) Pharmacogenes: Scientific Background and Clinical Applications.  Note: update of former title Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine.*
  Updated version of the book Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine

• Kisor DF, Kane, MD, Talbot JT, Sprague JE. (2013) Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine.  1^st Ed. Jones and Bartlett Learning.  Burlington, MA.*

Book Chapter (*Peer Reviewed):

• Kisor DF, Hoefer CC, Decker BS.  In Thomas D (ed).Pharmacogenomics and Precision Medicine in: Clinical Pharmacy Education, Practice and Research. 2018. Oxford, UK. 437-452.*
  

• Ray SD, Thomas KL, Kisor DF. ADRs, ADEs, and SEDs: A Bird’s Eye View. In:  Side Effects of Drugs Annual.  38^nd Ed. 2016.* 

• Ray SD, Beckett RD, Kisor DF, Gray JP, Kiersma ME. ADRs, ADEs, and SEDs: A Bird’s Eye View. In:  Side Effects of Drugs Annual.  37^nd Ed. 2015.* 

• Benedict N, Kisor DF.  The academic pharmacist in: Remington: The Science and Practice of Pharmacy.  22^nd Ed. 2229-2234, 2013.*

Papers (*Selected Peer Reviewed):

• Kisor DF, Bright DR, Smith TR, Wiisanen K. Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process. Washington DC. American Pharmacists Association (©2020).* 
  
• Design/writing/corresponding 


• Hilden M, Bright DR, Christensen H, Kisor DF. Red, Yellow, Green: Stop, Proceed with Caution, or Go with Pharmacogenomics -A Practical Primer for the Consultant Pharmacist. Senior Care Pharm. 34(6):363-369, 2019.*
  
• Role: Design/writing/corresponding


• Kisor DF, Farrell CL. Expanding pharmacist and student pharmacist access to genetics/genomics/pharmacogenomics competency education. Med Ed Curr Dev. https://doi.org/10.1177/2382120519834325 2019.*
  
• Role: Design/data analysis/writing/corresponding


• Grecco GG, Kisor DF; Sprague JE. Pharmacokinetic data of synthetic cathinones in female Sprague-Dawley rats. Data in Brief. 21:1045–1050, 2018.
  
• Role: Design/data analysis/writing


• Calinski DM, Kisor DF, Sprague JE. A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics. Psychopharmacology. https://doi.org/10.1007/s00213-018-4985-6, 2018.
  
• Role: Design/writing


• Kisor DF, Bodzin AS. Pharmacogenomics in liver transplantation: Testing the recipient and the ex-vivo donor liver. Pharmacogenomics. 19(9):753-756, 2018.
  
• Role: Design/writing/corresponding


• Beckett RD, Kisor DF, Smith T, Vonada B. Systematic evaluation of clinical practice guidelines for pharmacogenomics. Pharmacogenomics. 19(8):693-700, 2018.*
  
• Role: Evaluation/writing/review


• Hoefer CC, Brick EJ, MS, Savariar A, Kisor DF, Dawson A, Khatri A, Johnson J, Henriksen B. Allelic frequencies of 60 pharmacogene variants assessed within a Burmese Population residing in North East Indiana, U.S. Pharmacogenomics. 19(5):393-399, 2018.
  
• Role: Evaluation/writing/review


• Kisor DF, Calinski DM, Farrell CL. Beyond the didactic lecture: Pharmacogenomics in Pharmacy Education. Per Med. 15(1):9-12, 2018.
  
• Role: Design/writing (invited editorial)


• Bright DR, Greco AJ, Langerveld A, Kisor DF. Clinical Implementation of Personalized Medicine in Community Pharmacies: Considerations for Clinicians. Per Med. Published Online:24 Nov 2017https://doi.org/10.2217/pme-2017-0050 2017.
  
• Role: Design/writing (invited editorial)


• Grecco GG, Kisor DF, Magura JS, Sprague JE. Impact of common clandestine structural modifications on synthetic cathinone "bath salt" pharmacokinetics. Tox App Pharmacol 328:18-24, 2017.*
  
• Role: Design/data analysis/writing


• Beam TA, Loudermilk EF, Kisor DF. Pharmacogenetics and Pathophysiology of CACNA1S Mutations in Malignant Hyperthermia. Physiol Genomics. 49(2):81-87, 2017.*
  
• Role: Design/literature evaluation/writing/corresponding


• Roederer MW, Kuo GM, Kisor DF, Frye R, Hoffman JM, Jenkins J, Weitzel KW. Pharmacogenomics Competencies in Pharmacy Practice: A Blueprint for Change. J Am Pharm Assoc. 57(1):120-125, 2017.*
  
• Role: Design/literature evaluation/writing


• Smith TR, Kearney E, Hulick PJ, Kisor DF. History repeats itself: The Family Medication History and Pharmacogenomics. Pharmacogenomics. 17(7):669-678, 2016.*
  
• Role: Design/literature evaluation/writing/corresponding


• Calinski DM, Kisor DF. An Interdisciplinary Experience focused on Pharmacogenetics: Engaging pharmacy and physician assistant students in conversations about antiplatelet therapy with respect to CYP2C19 genotype. Innov Pharm. 7(1):1-5, 2016.*
  
• Role: Design/literature evaluation/writing/corresponding


• Banks ML, Smith DA; Kisor DF; Poklis JL. Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys. Pharmacol Biochem Behav. 141:58-65, 2016.*
  
• Role: Concentration-time data analysis/writing


• Kisor DF, Smith HE, Grace E, Johnson SG, Weitzel KW, Farrell CL. The DNA of Pharmacy Education: CAPE Outcomes and Pharmacogenomics. AACP 2016. Found at: http://www.aacp.org/resources/education/cape/Documents/The_DNA_of_Pharmacy_Education-CAPE_Outcomes_and_Pharmacogenomics_2015.pdf. Pgs. 1-38, 2016.*
  
• Role: Design/literature evaluation/writing


• Kisor DF, Bright DR, Manion CR, Smith TR. Pharmacogenomics: Overview of Applications and Relation to Infusion Therapy. J Inf Nurs. 39(3):139-148, 2016.*
  
• Role: Design/literature evaluation/writing/corresponding


• Bright DR, Calinski DM, Kisor DF. Pharmacogenetic considerations in the elderly. Consult Pharm. 30(4), 228-239, 2015.*
  
• Role: Design/literature evaluation/writing/corresponding


• Kisor DF, Bright DR, Chen J, Smith TR. Academic and Professional Pharmacy Education: A Pharmacogenomics Certificate Training Program. Pers Med. 12(6):563-573, 2015.*
  
• Role: Design/literature evaluation/writing/corresponding


• Henriksen B, Kisor DF. Improving the Tenure Committee’s Review Efficiency with Embedded Dossier Functionality. Innov Pharm. 6(3);1-23, 2015.*
  
• Role: Design/literature evaluation/writing/corresponding


• Bright DR, Kisor DF, Smith A, Conaway M, Yu M. Implementation of a Pharmacogenetic Management Service for Post-Myocardial Infarction Care in a Community Pharmacy. Pers Med. 12(4), 319-325, 2015.*
  
• Role: Design/DNA analysis/genotype interpretation/writing


• Westervelt P, Cho K, Bright DR, Kisor DF. Drug-Gene Interactions: Inherent Variability in Maintenance Dose Requirements. Pharm Ther. 39(9), 630-637, 2014.*
  
• Role: Design/literature evaluation/writing/corresponding


• Bova K, Bova S, Hill K, Dixon M, Ivankovic D, Kisor DF. Introducing Pharmaco-genetics and Personalized Medicine via a Weblog. Innov Pharm. 5(2);1-11, 2014.*
  
• Role: Design/literature evaluation/writing/corresponding


• Kisor DF, Bright DR, Conaway MM, Bouts BA, Gerschutz G. Pharmacogenetics in the Community Pharmacy: Thienopyridine Selection Post Coronary Artery Stent Placement. J Pharm Prac. 27(4);416-419. 2014.*
  
• Role: Design/DNA analysis/genotype interpretation/writing


• Kisor DF. Making personalized medicine an expectation of pharmacy students. Pers Med. 10(1):5-8, 2013. (invited editorial).
  
• Role: Design/writing


• Kisor DF, Smith AJ. Therapeutic Actions and the Genetic Code: Examples of the application of pharmacogenetics. Ohio Pharmacist 62(12):7-12, 2013.
  
• Role: Design/literature evaluation/writing


• Kisor DF, Kroustos K. Pharmacogenomics in women’s health. U.S. Pharmacist. 38(9):70-80, 2013.
  
• Role: Design/literature evaluation/writing


• Kisor DF, Tice B. Implementing pharmacogenomics in pharmacy practice. Am Pharmacist. 47-61, 2013.
  
• Role: Design/literature evaluation/writing


• Kisor DF, Sprague JE. The application of drug dosing guidelines based on preemptive genetic testing. Spec Pharm Times. 4(3), 2013.
  
• Role: Design/literature evaluation/writing


• Shields KM, Sobota KF, Kroustos KR, Bright DR, North CL, Kisor DF. Implementation and evaluation of a student-led, online, longitudinal outpatient case elective. Curr Pharm Teach Learn. 5(5);351-357, 2013.*
  
• Role: Design/literature evaluation/data analysis/writing/corresponding


• Kisor DF, Talbot JN, Stockert AL, Smith A. Exploring a laboratory model of pharmacogenetics as applied to clinical decision making. Innov Pharm. 4(2);1-12, 2013.*
  
• Role: Design/DNA analysis/genotype interpretation/writing


• Kisor DF, Munro C, Loudermilk E. Pharmacogenomics and the most commonly prescribed drugs of 2011. Pharm Times. 78(12):85-96, 2012.
  
• Role: Design/literature evaluation/writing


• Rojeab Y, Martin S, White R, Montenery S, McWilliams M, Walker M, Kisor D. In vitro dissolution and pilot pharmacokinetic studies of acetylsalicylic acid from an orally disintegrating tablet formulation of low-dose aspirin. Int J Med Clin Res. 2:72-77, 2011.*
  
• Role: Design/concentration-time data analysis/writing


• Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol. 4:133-151, 2010.*
  
• Role: Design/literature evaluation/writing


• Likovich M, Derr A, Kane M, Kisor DF, Sprague JE. Personalized medicine and the future of pharmacy practice. Pharm Times. 76(4), 2010.
  
• Role: Design/literature evaluation/writing


• Kisor DF. Collaboration to meet a therapeutic need: The development of nelarabine. Clin Med: Ther. 1:1317-1320, 2009. (invited editorial)
  
• Role: Design/literature evaluation/writing


• Reilly KM, Kisor DF. Profile on nelarabine: Use in the treatment of T-cell acute lymphoblastic leukemia. OncoTargets and Therapy. 2:219-228, 2009.*
  
• Role: Design/literature evaluation/writing/corresponding


• Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, MA Nader. Ambient temperature effects on 3,4-methylenedioxymethamphetamine (MDMA)-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Disp. 35:1840-1845, 2007.*
  
• Role: Design/concentration-time data analysis/writing


• Kisor DF. Nelarabine. Drugs of Today. 42(7):455-465, 2006.*
  
• Role: Design/literature evaluation/writing


• Allison JA, Roecker A, Kisor DF. Nelarabine. Fut Onc. 2(4)441-448, 2006.*
  
• Role: Design/literature evaluation/writing/corresponding


• Kisor DF. Nelarabine: A nucleoside analog with efficacy in T-cell and other leukemias. Ann Pharmacother. 39:1056-1063, 2005.*
  
• Role: Design/literature evaluation/writing


• Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin G, Krenitsky T, Elion G, Mitchell BS. A phase I study of 2-amino-9-Beta-D-arabinofuranosyl-6-methoxy-9H purine (506U78[Nelarabine]) administered on a consecutive five day schedule in children and adults with refractory hematological malignancies. J Clin Onc. 23(15):3396-3403, 2005.*
  
• Role: Design/concentration-time data analysis/writing


• Broedel-Zaugg K, Kisor DF, Sullivan DL. Evaluating the pharmaceutical industry’s need for graduates with a bachelor of science degree in pharmaceutical sciences. Am J Pharm Educ. 67(1):91-99, 2003.*
  
• Role: Design/data analysis/literature evaluation/writing


• Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, and Gandhi V. The pharmacokinetics of Nelarabine and 9-Beta-D-Arabinofuranosyl guanine in pediatric and adult patients receiving nelarabine during a phase I study of Nelarabine for the treatment of refractory hematological malignancies. J Clin Onc. 18:995-1003, 2000.*
  
• Role: Design/concentration-time data analysis/writing


• Sprague JE, Christoff J, Allison J, Kisor D, Sullivan D. Development and implementation of an integrated cardiovascular module in a Pharm.D. curriculum. Am J Pharm Educ. 64:20-26, 1999.*
  
• Role: Design/data analysis/literature evaluation/writing


• Gandhi V, Plunkett W, Rodriguez CO, Kisor, DF, Mitchell BS, Kurtzberg J, Keating MJ. A phase I study of GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Onc. 16;3607-3615, 1998.*
  
• Role: Design/concentration-time data analysis/writing


• Jewell, RC, Khor SP, Kisor DV, Krueger KA, Wargin WA. Pharmacokinetics of RheothRx injection in health male volunteers. J Pharm Sci. 86:808-812, 1997.*
  
• Role: Design/concentration-time data analysis/writing


• Schmith VD, Phillips L, Kisor DF, Fiedler-Kelly J, Weatherley BC. Pharmacokinetics/ Pharmacodynamics of cisatracurium in healthy adult patients. Cur Opin Anesth. 9:s9-s15, 1996.*
  
• Role: Design/concentration-time data analysis/writing


• De Wolf AM, Freeman JA, Scott VL, Tullock W, Smith DA, Kisor DF, Kerls S, Cook DR. The pharmacokinetics and pharmacodynamics of 51W89 in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth. 76:624-628, 1996.*
  
• Role: Design/concentration-time data analysis/writing


• Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ. Pharmacokinetics of 51W89 in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology. 84:300-308, 1996.*
  
• Role: Design/concentration-time data analysis/writing


• Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ptachcinski R, Kisor D, Ondick L, Felser I, Irish W, Fung J, Starzl T. A short early course of ganciclovir prevents both cytomegalovirus infection and disease in adult liver transplant patients. Transplantation. 58:779-785, 1994.*
  
• Role: Data analysis/writing


• Kisor DF, Frye RF, Kudsk KA. Estimation of the hepatic extraction ratio of indocyanine green in swine. Clin Sci. 84:681-685, 1993.*
  
• Role: Design/concentration-time data analysis/writing